Baseline Cardiovascular Risk Factor Control in Patients With Type 2 Diabetes and Coronary Disease Versus Stroke: Secondary Analysis of Cardiovascular Outcome Trials
Balasubramanian P, Kernan W, Sheth K, Ofstad A, Rosenstock J, Wanner C, Zinman B, Mattheus M, Marx N, Inzucchi S. Baseline Cardiovascular Risk Factor Control in Patients With Type 2 Diabetes and Coronary Disease Versus Stroke: Secondary Analysis of Cardiovascular Outcome Trials. Stroke 2023, 54: 2013-2021. PMID: 37449424, PMCID: PMC10358436, DOI: 10.1161/strokeaha.122.042053.Peer-Reviewed Original ResearchConceptsCardiovascular risk factor controlRisk factor controlCoronary artery diseaseEMPA-REG OUTCOMECardiovascular outcome trialsType 2 diabetesRisk factorsOutcome trialsBlood pressureOdds ratioAntiplatelet/anticoagulant medicationsAntiplatelet/anticoagulant therapyDiabetes cardiovascular outcome trialsSuboptimal risk factor controlCardiovascular risk factorsRecurrent ischemic eventsDiastolic blood pressureSystolic blood pressureRespective odds ratiosFactor controlCross-sectional analysisLogistic regression modelsMacrovascular complicationsStatin useAnticoagulant medicationChapter 13 Sodium-glucose Co-transporter-2 inhibitors: a new era of cardioprotection and renoprotection
Balasubramanian P, Inzucchi S. Chapter 13 Sodium-glucose Co-transporter-2 inhibitors: a new era of cardioprotection and renoprotection. 2023, 337-363. DOI: 10.1016/b978-0-323-99991-5.00006-1.Peer-Reviewed Original ResearchSGLT2 inhibitorsType 2 diabetesSodium-glucose cotransporter 2 inhibitorsGlucose cotransporter 2 inhibitorsLarge cardiovascular outcome trialsInduction of glucosuriaRenal protective benefitsCardiovascular risk factorsGlucose-lowering medicationsCardiovascular outcome trialsCotransporter 2 inhibitorsClinical practice guidelinesMechanism of actionRenal benefitsCardiorenal benefitsDiabetes statusOutcome trialsBlood pressureChronic kidneyHeart failureRisk factorsLipid profileCardiovascular diseasePractice guidelinesBody weight